Cognitive function in postmenopausal women receiving adjuvant letrozole or tamoxifen for breast cancer in the BIG 1-98 randomized trial

被引：65

作者：

Phillips, Kelly-Anne ^{[3
,4
]}

Ribi, Karin ^{[1
]}

Sun, Zhuoxin ^{[5
]}

Stephens, Alisa ^{[6
]}

Thompson, Alastair ^{[7
]}

Harvey, Vernon ^{[8
]}

Thuerlimann, Beat ^{[9
,10
]}

Cardoso, Fatima ^{[11
]}

Pagani, Olivia ^{[10
,12
]}

Coates, Alan S. ^{[13
,14
]}

Goldhirsch, Aron ^{[15
,16
]}

Price, Karen N. ^{[17
]}

Gelber, Richard D. ^{[5
,17
]}

Bernhard, Juerg ^{[1
,2
]}

机构：

[1] IBCSG Coordinating Ctr, CH-3008 Bern, Switzerland

[2] Univ Hosp Bern, Inselspital, Dept Med Oncol, CH-3010 Bern, Switzerland

[3] Peter MacCallum Canc Ctr, Melbourne, Vic, Australia

[4] Univ Melbourne, Melbourne, Vic, Australia

[5] Dana Farber Canc Inst, IBCSG Stat Ctr, Boston, MA 02115 USA

[6] Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA

[7] Univ Dundee, Ninewells Hosp, Dundee, Scotland

[8] Auckland City Hosp, Auckland, New Zealand

[9] Kantonsspital, Breast Ctr, St Gallen, Switzerland

[10] Swiss Grp Clin Canc Res SAKK, Bern, Switzerland

[11] Inst Jules Bordet, Dept Med Oncol, B-1000 Brussels, Belgium

[12] Osped Italian, Oncol Inst So Switzerland, Lugano, Switzerland

[13] IBCSG, Bern, Switzerland

[14] Univ Sydney, Sydney, NSW 2006, Australia

[15] European Inst Oncol, Dept Med, Milan, Italy

[16] Oncol Inst So Switzerland, Bellinzona, Switzerland

[17] Frontier Sci & Technol Res Fdn Inc, Boston, MA USA

来源：

BREAST | 2010年 / 19卷 / 05期

基金：

美国国家卫生研究院;

关键词：

Cognitive function; Breast cancer; Aromatase inhibitor; Tamoxifen; Letrozole; Quality of life; THERAPY; MEMORY; ESTROGEN; ANASTROZOLE; IMPAIRMENT; ESTRADIOL; DEMENTIA; BRAIN; RATS;

D O I：

10.1016/j.breast.2010.03.025

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Cognitive function in postmenopausal women receiving letrozole or tamoxifen as adjuvant endocrine treatment was compared during the fifth year of treatment in a substudy of the BIG 1-98 trial. In BIG 1-98 patients were randomized to receive adjuvant (A) 5-years tamoxifen, (B) 5-years letrozole, (C) 2-years tamoxifen followed by 3-years letrozole, or (D) 2-years letrozole followed by 3-years tamoxifen. The primary comparison was the difference in composite score for patients taking letrozole (B + C: N = 65) vs. tamoxifen (A + D; N = 55). The patients taking letrozole had better overall cognitive function than those taking tamoxifen (difference in mean composite z-scores = 0.28, P = 0.04, 95% Cl: 0.02, 0.54, Cohen's D = 0.40 indicating small to moderate effect). In this substudy, breast cancer patients taking adjuvant letrozole during the fifth year of treatment had better cognitive function than those taking tamoxifen, suggesting aromatase inhibitors do not adversely impact cognition compared with tamoxifen. (C) 2010 Elsevier Ltd. All rights reserved.

引用

页码：388 / 395

页数：8

共 50 条

[1] Cognitive function in postmenopausal women receiving adjuvant letrozole or tamoxifen in the Breast International Group (BIG) 1-98 trial
Ribi, K. E.
Phillips, K. A.
Sun, Z.
Stephens, A.
Thompson, A.
Harvey, V.
Thuerlimann, B.
Cardoso, F.
Coates, A. S.
Bernhard, J.
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
[2] Changes in cognitive function in postmenopausal women 1 year after completing adjuvant letrozole or tamoxifen in the Breast International Group (BIG) 1-98 trial.
Ribi, K.
Aldridge, J.
Phillips, K.
Sun, Z.
Thompson, A. M.
Harvey, V. J.
Thuerlimann, B.
Cardoso, F.
Coates, A. S.
Bernhard, J.
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
[3] Cognitive function in postmenopausal breast cancer patients one year after completing adjuvant endocrine therapy with letrozole and/or tamoxifen in the BIG 1-98 trial
Phillips, Kelly-Anne
Aldridge, Julie
Ribi, Karin
Sun, Zhuoxin
Thompson, Alastair
Harvey, Vernon
Thuerlimann, Beat
Cardoso, Fatima
Pagani, Olivia
Coates, Alan S.
Goldhirsch, Aron
Price, Karen N.
Gelber, Richard D.
Bernhard, Juerg
[J]. BREAST CANCER RESEARCH AND TREATMENT, 2011, 126 (01) : 221 - 226
[4] Cognitive function in postmenopausal breast cancer patients one year after completing adjuvant endocrine therapy with letrozole and/or tamoxifen in the BIG 1-98 trial
Kelly-Anne Phillips
Julie Aldridge
Karin Ribi
Zhuoxin Sun
Alastair Thompson
Vernon Harvey
Beat Thürlimann
Fatima Cardoso
Olivia Pagani
Alan S. Coates
Aron Goldhirsch
Karen N. Price
Richard D. Gelber
Jürg Bernhard
[J]. Breast Cancer Research and Treatment, 2011, 126 : 221 - 226
[5] 12 years' median follow up (MFU) of BIG 1-98: Adjuvant letrozole, tamoxifen and their sequence for postmenopausal women with endocrine responsive early breast cancer
Thuerlimann, B.
Giobbie-Hurder, A.
Colleoni, M.
Jensen, M-B
Ejlertsen, B.
de Azambuja, E.
Neven, P.
Lang, I.
Gladieff, L.
Bonnefoi, H.
Harvey, V. J.
Spazzapan, S.
Tondini, C.
Price, K.
Piccart-Gebhart, M.
Regan, M. M.
Gelber, R. D.
Coates, A. S.
Goldhirsch, A.
[J]. CANCER RESEARCH, 2017, 77
[6] Prognostic and predictive importance of the estrogen receptor coactivator AIB1 in a randomized trial comparing adjuvant letrozole and tamoxifen therapy in postmenopausal breast cancer: the Danish cohort of BIG 1-98
Alkner, S.
Jensen, M. -B.
Rasmussen, B. B.
Bendahl, P. -O.
Ferno, M.
Ryden, L.
Mouridsen, H.
[J]. BREAST CANCER RESEARCH AND TREATMENT, 2017, 166 (02) : 481 - 490
[7] Prognostic and predictive value of centrally reviewed expression of estrogen and progesterone receptors in a randomized trial comparing letrozole and tamoxifen adjuvant therapy for postmenopausal early breast cancer:: BIG 1-98
Viale, Giuseppe
Regan, Meredith M.
Maiorano, Eugenio
Mastropasqua, Mauro G.
Dell'Orto, Patrizia
Rasmussen, Birgitte Bruun
Raffoul, Johnny
Neven, Patrick
Orosz, Zsolt
Braye, Stephen
Oehlschlegel, Christian
Thuerlimann, Beat
Gelber, Richard D.
Castiglione-Gertsch, Monica
Price, Karen N.
Goldhirsch, Aron
Gusterson, Barry A.
Coates, Alan S.
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (25) : 3846 - 3852
[8] Prognostic and predictive importance of the estrogen receptor coactivator AIB1 in a randomized trial comparing adjuvant letrozole and tamoxifen therapy in postmenopausal breast cancer: the Danish cohort of BIG 1-98
S. Alkner
M.-B. Jensen
B. B. Rasmussen
P.-O. Bendahl
M. Fernö
L. Rydén
H. Mouridsen
[J]. Breast Cancer Research and Treatment, 2017, 166 : 481 - 490
[9] Adjuvant Letrozole and Tamoxifen Alone or Sequentially for Postmenopausal Women With Hormone Receptor-Positive Breast Cancer: Long-Term Follow-Up of the BIG 1-98 Trial
Ruhstaller, Thomas
Giobbie-Hurder, Anita
Colleoni, Marco
Jensen, Maj-Britt
Ejlertsen, Bent
de Azambuja, Evandro
Neven, Patrick
Lang, Istvan
Jakobsen, Erik Hugger
Gladieff, Laurence
Bonnefoi, Herve
Harvey, Vernon J.
Spazzapan, Simon
Tondini, Carlo
Del Mastro, Lucia
Veyret, Corinne
Simoncini, Edda
Gianni, Lorenzo
Rochlitz, Christoph
Kralidis, Elena
Zaman, Khalil
Jassem, Jacek
Piccart-Gebhart, Martine
Di Leo, Angelo
Gelber, Richard D.
Coates, Alan S.
Goldhirsch, Aron
Thuerlimann, Beat
Regan, Meredith M.
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (02) : 105 - +
[10] Outcomes of special histotypes of breast cancer after adjuvant endocrine therapy with letrozole or tamoxifen in the monotherapy cohort of the BIG 1-98 trial
Munzone, E.
Giobbie-Hurder, A.
Gusterson, B. A.
Mallon, E.
Viale, G.
Thurlimann, B.
Ejlertsen, B.
MacGrogan, G.
Bibeau, F.
Lelkaitis, G.
Price, K. N.
Gelber, R. D.
Coates, A. S.
Goldhirsch, A.
Colleoni, M.
[J]. ANNALS OF ONCOLOGY, 2015, 26 (12) : 2442 - 2449

← 1 2 3 4 5 →